Michael Rosenbloom1, Soo Borson1, Terry Barclay1, Leah R Hanson1, Ann Werner1, Logan Stuck1, John McCarten1. 1. HealthPartners Center for Memory and Aging (MR, TB, LRH), St. Paul; Department of Neurology (MR, JM), University of Minnesota Medical School, Minneapolis; Geriatric Research, Education and Clinical Center (GRECC) (JM), Minneapolis VA Health Care System, MN; the University of Washington School of Nursing (SB), University of Washington School of Medicine, Seattle; and HealthPartners Institute for Research and Education (LRH, AW, LS), Bloomington, MN.
Abstract
BACKGROUND: Alzheimer disease is one of the most prevalent and costly neurologic disorders. American Academy of Neurology guidelines call for diagnosis and treatment when dementia is present, but provide no specific instruction relating to cognitive screening. METHODS: Our center piloted a cognitive screening initiative using the Mini-Cog, which was administered to all neurology patients aged ≥70 years without a history of a cognitive disorder. RESULTS: There was a 37.4% screen positive rate on the Mini-Cog. The percentage of patients with subjective memory complaints did not differ between patients screening positive vs negative on the Mini-Cog. Prospective analysis over an 18-month postscreening period showed that individuals screening positive for cognitive impairment were 10 times more likely to have follow-up cognitive assessment by the provider (p < 0.0001), almost 3 times more likely to be referred for neuropsychological testing (p = 0.003), and 3 times more likely to receive a diagnosis of cognitive impairment or dementia (p < 0.0001) compared to those screening negative. Diagnosis of a cognitive disorder, referral to a cognitive specialty clinician, and prescription of cognitive-enhancing medications were no more frequent than was observed in a randomized trial of screening in primary care, and evidence of neurologists' actions relevant to cognitive impairment was found in a minority of individuals screening positive. CONCLUSION: Further studies are needed to better understand factors influencing neurologist actions in the evaluation and treatment of cognitive impairment.
RCT Entities:
BACKGROUND:Alzheimer disease is one of the most prevalent and costly neurologic disorders. American Academy of Neurology guidelines call for diagnosis and treatment when dementia is present, but provide no specific instruction relating to cognitive screening. METHODS: Our center piloted a cognitive screening initiative using the Mini-Cog, which was administered to all neurology patients aged ≥70 years without a history of a cognitive disorder. RESULTS: There was a 37.4% screen positive rate on the Mini-Cog. The percentage of patients with subjective memory complaints did not differ between patients screening positive vs negative on the Mini-Cog. Prospective analysis over an 18-month postscreening period showed that individuals screening positive for cognitive impairment were 10 times more likely to have follow-up cognitive assessment by the provider (p < 0.0001), almost 3 times more likely to be referred for neuropsychological testing (p = 0.003), and 3 times more likely to receive a diagnosis of cognitive impairment or dementia (p < 0.0001) compared to those screening negative. Diagnosis of a cognitive disorder, referral to a cognitive specialty clinician, and prescription of cognitive-enhancing medications were no more frequent than was observed in a randomized trial of screening in primary care, and evidence of neurologists' actions relevant to cognitive impairment was found in a minority of individuals screening positive. CONCLUSION: Further studies are needed to better understand factors influencing neurologist actions in the evaluation and treatment of cognitive impairment.
Authors: J Riley McCarten; Pauline Anderson; Michael A Kuskowski; Susan E McPherson; Soo Borson Journal: J Am Geriatr Soc Date: 2011-02 Impact factor: 5.562
Authors: Kelvin K F Tsoi; Joyce Y C Chan; Hoyee W Hirai; Samuel Y S Wong; Timothy C Y Kwok Journal: JAMA Intern Med Date: 2015-09 Impact factor: 21.873
Authors: D S Knopman; S T DeKosky; J L Cummings; H Chui; J Corey-Bloom; N Relkin; G W Small; B Miller; J C Stevens Journal: Neurology Date: 2001-05-08 Impact factor: 9.910
Authors: Soo Borson; James Scanlan; Jeffrey Hummel; Kathy Gibbs; Mary Lessig; Elizabeth Zuhr Journal: J Gen Intern Med Date: 2007-04-20 Impact factor: 5.128
Authors: Jennifer S Lin; Elizabeth O'Connor; Rebecca C Rossom; Leslie A Perdue; Elizabeth Eckstrom Journal: Ann Intern Med Date: 2013-11-05 Impact factor: 25.391
Authors: Michael Rosenbloom; Terry R Barclay; Soo Borson; Ann M Werner; Lauren O Erickson; Jean M Crow; Kamakshi Lakshminarayan; Logan H Stuck; Leah R Hanson Journal: J Gen Intern Med Date: 2018-08-10 Impact factor: 5.128
Authors: William Perry; Laura Lacritz; Tresa Roebuck-Spencer; Cheryl Silver; Robert L Denney; John Meyers; Charles E McConnel; Neil Pliskin; Deb Adler; Christopher Alban; Mark Bondi; Michelle Braun; Xavier Cagigas; Morgan Daven; Lisa Drozdick; Norman L Foster; Ula Hwang; Laurie Ivey; Grant Iverson; Joel Kramer; Melinda Lantz; Lisa Latts; Shari M Ling; Ana Maria Lopez; Michael Malone; Lori Martin-Plank; Katie Maslow; Don Melady; Melissa Messer; Randi Most; Margaret P Norris; David Shafer; Nina Silverberg; Colin M Thomas; Laura Thornhill; Jean Tsai; Nirav Vakharia; Martin Waters; Tamara Golden Journal: Arch Clin Neuropsychol Date: 2018-09-01 Impact factor: 2.813
Authors: William Perry; Laura Lacritz; Tresa Roebuck-Spencer; Cheryl Silver; Robert L Denney; John Meyers; Charles E McConnel; Neil Pliskin; Deb Adler; Christopher Alban; Mark Bondi; Michelle Braun; Xavier Cagigas; Morgan Daven; Lisa Drozdick; Norman L Foster; Ula Hwang; Laurie Ivey; Grant Iverson; Joel Kramer; Melinda Lantz; Lisa Latts; Shari M Ling; Ana Maria Lopez; Michael Malone; Lori Martin-Plank; Katie Maslow; Don Melady; Melissa Messer; Randi Most; Margaret P Norris; David Shafer; Nina Silverberg; Colin M Thomas; Laura Thornhill; Jean Tsai; Nirav Vakharia; Martin Waters; Tamara Golden Journal: Innov Aging Date: 2018-10-12